Artal Group S.A. Y M Abs Therapeutics, Inc. Transaction History

Artal Group S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	BUY	$29.16 - $51.96 $3.35 Million - $5.97 Million	114,972 Added 40.34%	400,000 $12.1 Million
Q3 2020 Nov 13, 2020	SELL	$35.13 - $43.62 $527,020 - $654,387	-15,002 Reduced 5.0%	285,028 $10.9 Million
Q2 2020 Aug 14, 2020	SELL	$23.66 - $49.53 $2.37 Million - $4.95 Million	-99,970 Reduced 24.99%	300,030 $13 Million
Q2 2019 Aug 09, 2019	BUY	$19.51 - $28.31 $7.8 Million - $11.3 Million	400,000 New	400,000 $9.15 Million
Q1 2019 May 10, 2019	SELL	$18.21 - $26.21 $910,500 - $1.31 Million	-50,000 Closed	0 $0
Q4 2018 Feb 11, 2019	SELL	$15.41 - $28.92 $1.54 Million - $2.89 Million	-100,000 Reduced 66.67%	50,000 $1.02 Million
Q3 2018 Nov 09, 2018	BUY	$24.0 - $26.97 $3.6 Million - $4.05 Million	150,000 New	150,000 $3.98 Million

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.